New hope for ruptured liver cancer: drug combo aims to stop recurrence

NCT ID NCT07331883

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether two drugs, sintilimab and bevacizumab, given after surgery can prevent cancer from coming back in people with ruptured liver cancer. About 35 participants will receive the combination every three weeks. The goal is to see if this approach is safe and improves how long people live without their cancer returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sintilimab and bevacizumab biosimilar
What this could lead to: If this works, it could provide a new treatment option to lower the risk of cancer returning after surgery for ruptured liver cancer.
What could go wrong: This is a small, early-phase study with only 35 participants and no comparison group. The combination may cause side effects and might not prove effective in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Huashan Hospital, Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200031, China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200025, China
Sanming First Hospital
NOT_YET_RECRUITING

Sanming, Fujian, 365000, China
The Third Bethune Hospital of Jilin University
RECRUITING

Changchun, Jilin, 130033, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.